Clinical and economic analysis of public procurement of anti-tuberculosis medicines for treatment of patients with multi-resistant tuberculosis
DOI:
https://doi.org/10.24959/uekj.20.15Keywords:
clinical and economic analysis, public procurement, anti-tuberculosis medicines, multidrug-resistant tuberculosisAbstract
Aim. To make clinical and economic analysis of tender procurement of drugs for the treatment of patients with multiple resistance tuberculosisinUkraine.
Materials and methods. The Ministry of Health of Ukraine for the years 2014-2018 on the volume of public purchases of anti-tuberculosis medicines has been used for the study. The total amount of public purchases of anti-tuberculosis medicines by all trade names, groupings of purchases by international non-proprietary nameshas been determined. During the study, the following methods of clinical and economic analysis used: ABC, XYZ, VEN-analyzes, integrated ABC/XYZ, ABC/VEN, U1U2U3U0/ABC-analyzes. Based on the results of integrated analyzes, matrix projections have been formed.
Results. According to the results of the ABC-public procurement analysis of tuberculosis medicines for 2014-2018, it was found that the total cost of purchasing medicines for the treatment of patients with multidrug-resistant tuberculosis had uneven dynamics. It is proved that during 2014-2018 the group A is dominated by anti-tuberculosis medicines of foreign production. The results of the matrix projection analysis of the integrated ABC/XYZ analysis show that, with significant financial costs for the procurement of anti-TB drugs, the frequency of purchases is unpredictable. Based on the results of the VEN analysis, it is proved that public procurement is carried out in compliance with the requirements of the relevant legal framework. The integrated ABC/VEN analysis demonstrates that during 2014-2015, the cost share for group A/E (meropon) was higher than for group A/V (levofloxacin, moxifloxacin, capreomycin), which does not fully meet the criteria of rational procurement. According to the results of the analysis of the matrix projection of the integrated U1U2U3U0/ABC-analysis, it is established that the group of not recommended medicines for the treatment of patients with multidrug-resistant tuberculosis includes three ATM (kanamycin, capreomycin, ofloxacin) with a cost amount of UAH 42520.3 thousand (part – 8.5 %).
Conclusions. Based on the results of a retrospective clinical and economic analysis of public procurement of anti-tuberculosis medicines for the period 2014-2018, it is possible to state the need for scientific substantiation for outpatient model providing medical and pharmaceutical assistance to patients with MRTB in accordance with their real needs in certain names of ATM health care capabilities and international standards.References
Zakon Ukrainy № 1287 vid 18.11.2003 r. (2003). Pro ratyfikatsiiu Uhody pro pozyku (Proekt «Kontrol za tuberkulozom ta VIL/SNIDom v Ukraini») mizh Ukrainoiu ta Mizhnarodnym bankom rekonstruktsii ta rozvytku. Available at: https://zakon.rada.gov.ua/laws/show/1287-15
Zakon Ukrainy № 2586 vid 28.12.2015 r. (2015). Pro protydiiu zakhvoriuvanniu na tuberkuloz. Available at: https://zakon.rada.gov.ua/laws/show/2586-1
WHO releases the new International Classification of Diseases (ICD 11). (n.d.). World Health Organization (en-US).
Health systems expanding in the context of Health 2020: challenges and priorities in the WHO European Region (2015). Division of Health Systems and Public Health, World Health Organization, 3–4.
Rozporiadzhennia Kabinetu Ministriv Ukrainy vid 30.11.2016 № 1013-r. (2016). Pro skhvalennia Kontseptsii reformy finansuvannia systemy okhorony zdorovia. Available at: http://zakon3.rada.gov.ua/laws/show/1013-2016-%D1%80.
Kabachna, A. V., Shelkova, E. V., Kabachnyi, O. G. (2015). Indeks utylitarnosti yak indykator otsinky dotsilnosti vnesennia likarskykh zasobiv do lokalnoho formuliara. Menedzhment ta marketynh u skladi suchasnoi ekonomiky, nauky i osvity, praktyky: III nauk.–prakt. Internet–konf. Kharkiv, 118–120.
Yakovlieva, L. V., Herasymova, O. O., Horbachova, A. S., Krasiuk, A. A. (2015). Kliniko–ekonomichni aspekty farmakoterapii khvorykh na vyrazkovu khvorobu shlunka. Farmatsevtychnyi chasopys, 3, 83–87. https://doi.org/10.11603/2312-0967.2015.3.4939
Kotvitska, A. A., Krasulia, O. I., Kubarieva, I.V. (2012). Naukovo-praktychni pidkhody do stvorennia lokalnoho formuliaru likarskykh zasobiv u likuvalno-profilaktychnykh zakladakh statsionarnoho typu. Management, economy and quality assurance in pharmacy, 6, 70–75.
Kotvitska, A. A., Kononenko, O. V. (2015). Otsinka farmakoterapii khvorykh na kir v umovakh statsionaru metodamy ABC–, VEN– ta chastotnoho analizu. Farmatsevtychnyi zhurnal, 6, 3–9.
Mnushko, Z. M., Sholoiko, N. V. (2008). Farmakoeoknomichni pidkhody do stvorennia optymalnoho pereliku likarskykh preparativ, neobkhidnykh dlia zakupivli za biudzhetni koshty (na prykladi hematolohichnoho viddilennia klinichnoi likarni): metod. rek. Kharkiv: NFaU, 19.
Panfilova, H. L., Tsurikova, O. V. (2014). Rezultaty doslidzhennia tendernykh zakupivel likarskykh zasobiv dlia onkohematolohichnykh khvorykh v Ukraini. Zaporizkyi medychnyi zhurnal, 1(82), 98–103.
Panfilova, G., Tsurikova, O., Dorovskyy, O., & Korzh, Y. (2015). The results of clinical and economic analysis of drug consumption in patients with acute lymphoid and myeloid leukemia in Ukraine. Clinical Pharmacy, 19(4), 17–23. http://dx.doi.org/10.24959/cphj.15.1361
Nemchenko, A. S., Nazarkina, V. N., & Kurylenko, Y. Y. (2018). The study of the state of pharmaceutical provision for patients with cardiovascular diseases using ABC- and VEN-analyses. News of Pharmacy, 3(95), 44–48. https://doi.org/10.24959/nphj.18.2218
Nemchenko, A. S. Kosiachenko, K. L., Panfilova, H. L. (2011). Metodyka provedennia kliniko-ekonomichnoho analizu tendernykh zakupivel LZ za derzhavnymy tsilovymy prohramamy: metodychni rekomendatsii. Kharkiv: NFAU, 26.
Sadova, D. T., Hrom, O. L. (2010). Optymizatsiia metodyky rozrakhunku potreby v protytuberkuloznykh preparatakh na osnovi analizu kart istorii khvoroby. Farmatsevtychnyi zhurnal, 4, 27–31.
Fedyak, I., Kupnovytska, I., & Hrynyk, N. (2018). Clinical and economic evaluation of pharmacotherapy of patients with tuberculosis in intensive therapy departments of antituberculosis dispensaries. Social Pharmacy In Health Care, 4(2), 19–28. http://dx.doi.org/10.24959/sphhcj.18.114
Nakaz MOZ Ukrainy vid 04.09.2014 r. № 620. (2014). Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy doroslym. Tuberkuloz. Available at: http://mtd.dec.gov.ua/images/dodatki/2014_620_TB/2014_620_YKPMD_TB.pdf
WHO. (n.d.). Available at: https://www.who.int/en
Feshchur, R. V., Barvinskyi, A. F., Kichor, V. P. (2003). Statystyka: teoretychni zasady i prykladni aspekty: navch. posib. Nats. un-t «Lvivska politekhnika», In-t piliadyplom. osvity. Lviv : Intelekt-Zakhid, 576.
Nakaz MOZ Ukrainy vid 29.12.2016 № 1422. (2016). Pro vnesennia zmin do nakazu Ministerstva okhorony zdorov’ia Ukrainy vid 28 veresnia 2012 roku № 755. Available at: https://zakon.rada.gov.ua/laws/show/z0530-17
Zakon Ukrainy № 2586 vid 28.12.2015 r. (2015). Pro protydiiu zakhvoriuvanniu na tuberkuloz. Available at: https://zakon.rada.gov.ua/laws/show/2586-14
Downloads
Published
Issue
Section
License
Copyright (c) 2020 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
